All
Botulinum toxin long-term safety study finds 'no news is good news'
September 1st 2004New York - Results of a retrospective review reinforce the long-term safety and tolerability of repeated treatments with botulinum toxin type A (Botox Cosmetic?, Allergan) for cosmetic reasons, said Alastair Carruthers, M.D., at the American Academy of Dermatology's Academy '04 here recently.
Novel agent, chemotherapy promising in melanoma tx
September 1st 2004New Orleans - BAY 43-9006, a novel signal transduction inhibitor, has very modest activity as a single agent in melanoma; however, it has promising activity in combination with chemotherapy, investigators said at the annual meeting of the American Society of Clinical Oncology (ASCO).
Biologics promise efficacy, convenience but few studied for indication in children
September 1st 2004Charleston, S.C. - Biologic agents for pediatric dermatology offer the promise of being safer and much easier to use than traditional drugs, according to Elaine C. Siegfried, M.D., associate clinical professor of pediatrics and dermatology at St. Louis University School of Medicine, Mo.
Legislation to improve patient safety; create “safe environment”
September 1st 2004Dermatologists and other healthcare providers are soon expected to have a formal mechanism for reporting medical errors and near misses without having to worry that the information will be used against them in a lawsuit.
Researchers make inroads in combination immunotherapy for melanoma
September 1st 2004New York - Melanoma-derived peptide vaccines are currently an exciting area of melanoma immuno-therapy research, according to Douglas J. Schwartzentruber, M.D., medical director and director of the Center for Cancer Care at Goshen Health System, Goshen, Ind., speaking at the Society of Surgical Oncology annual meeting.
Novel patch delivers local anesthesia with convenience, quickness, safety
September 1st 2004New York-An easy-to-use, self-warming patch containing lidocaine and tetracaine provides effective local anesthesia for minor dermatological procedures in adult patients, said Brian Berman, M.D., Ph.D, at the American Academy of Dermatology's Academy '04 meeting here.
Melasma treatments - from frustration to fruition?
September 1st 2004Eilat, Israel - For the last 50 years, hydroquinone has been the reference of treatment in hyperpigmentations, and more recently, combination formulas, peelings and adjuvant therapies including sunscreens containing the drug, show promise. However, topical agents have yet to prove a constant and uncontested efficiency, said Daphne Thioly-Bensoussan M.D., during the 28th Annual Meeting of the Israeli Conference of Dermatology and Venerology.
Tacrolimus bests pimecrolimus for treatment of AD, study says
September 1st 2004Kona, Hawaii - Tacrolimus ointment is superior to pimecrolimus cream in treating atopic dermatitis, according to recent trial data reported by Alan Fleischer, M.D., during the 28th Annual Hawaii Dermatology Seminar here. Both calcineurin inhibitors have identical modes of action and identical metabolism, and bind to the same FKBP receptor. "But pimecrolimus has one-third the binding affinity of tacrolimus," he says.
Savvy physician takes walk on entrepreneurial side
September 1st 2004Finally - and perhaps most crucial, says Dr. Goode - there is this question: Is there anything like the new device available? Because if there isn't, the new device could draw the attention of manufacturing or distributing companies.
Success starts outside operating room
August 1st 2004Stanford, Calif. - To be truly successful in a cosmetic surgery dermatology practice, it is important to think beyond garnering surgical ability. While such ability is essential, it is not the only aspect of a practice that surgeons should think about, says David R. Harris, M.D., a clinical professor at Stanford University School of Medicine.